Related Experiment Video

Updated: Aug 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

[Molecular targeting drugs--present status and future development]

Michihiko Kuwano1, Teruhiko Fujii, Mayumi Ono

  • 1Research Center for Innovative Cancer Therapy, Kurume University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 31, 2004
PubMed

Insights

Molecular targeting drugs offer novel cancer therapies by targeting specific molecules like EGF receptor. Further research is needed to determine efficacy, identify new targets, and optimize combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Context:

  • Molecular targeting drugs represent a significant advancement in cancer therapy.
  • Numerous molecular targets, including EGF receptor family proteins, Bcr-abl, CD20, and Ras, are being investigated for drug development.
  • Several targeted drugs are currently approved or in clinical trials for cancer treatment.

Purpose:

  • To highlight the potential of molecular targeting drugs in cancer therapeutics.
  • To identify key challenges and future research directions in the field.
  • To address critical questions regarding evidence-based efficacy determination, promising new targets, and optimal combination therapy design.

Summary:

  • Molecular targeting drugs exploit specific molecules driving cancer malignancy.
  • Approved and investigational drugs target key molecules like EGF receptor, Bcr-abl, CD20, and Ras.
  • Overcoming challenges in efficacy assessment, target identification, and combination therapy is crucial for advancing this strategy.

Impact:

  • Molecular targeting drugs offer a novel therapeutic strategy for cancer patients.
  • Continued research is essential to refine treatment protocols and expand the application of targeted therapies.
  • Addressing current limitations will enhance the effectiveness and applicability of molecularly targeted cancer treatments.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...